Charles River Laboratories International (CRL) Revenue — Quarter Ended Apr 1, 2023

Revenue for the quarter declined compared to the immediately preceding quarter, but rose compared to the same quarter one year earlier. The company's filing discusses risks encompassing non-human primate supply chain diversification and ongoing U.S. Department of Justice investigations.

Key takeaway

Quarter ended Apr 1, 2023 · FY2023 Q1

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$1B

Revenue reported for this quarter.

Quarter-over-quarter

-6.4%

Change from the immediately preceding quarter.

Year-over-year

+12.6%

Change from the comparable year-ago quarter.

Trailing four quarters

$4.1B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period ended	Revenue	Year-over-year change
Jun 25, 2022	$973.1M	+6.4%
Sep 24, 2022	$989.2M	+10.4%
Dec 31, 2022	$1.1B	+21.5%
Apr 1, 2023	$1B	+12.6%

Revenue performance

Reported revenue decreased from the prior quarter, reflecting a reversal of the sequential growth seen in recent periods. On a trailing twelve-month basis, revenue remained above the level of the comparable prior-year period.

Quarterly comparison

Compared with the immediately preceding quarter, revenue contracted. In contrast, compared with the same quarter one year ago, revenue expanded. The filing provides no explicit explanation for these movements beyond forward-looking statements regarding operational risks.

What to watch

The company highlights uncertainties around non-human primate supply chain diversification and the outcome of U.S. Department of Justice investigations, which may affect future performance.